Castaigne S, Sigaux F, Degos L, Flandrin G
Department of Clinical Hematology, Institut de Recherche sur les Maladies du Sang, Hôpital Saint-Louis, Paris, France.
Nouv Rev Fr Hematol (1978). 1989;31(5):321-5.
Between May 84 and December 85, 61 patients were treated for hairy cell leukemia by (recombinant or natural) alpha-IFN in a single institution. The responses obtained after 7 or 12 months of treatment are presented and the follow-up of the 39 patients for whom the treatment had been stopped for more than 12 months is evaluated. Neither clinical or histological parameters at presentation nor the type of timing of the interferon used allowed to predict the quality of response. The median time-lapse before the occurrence of neutropenia below 1.10(9)/l in patients with normal blood counts at the end of treatment was 12 months. However early relapses after the treatment stop were observed more frequently in patients with initially severe neutropenia or hyperleucocytosis. The therapeutic strategy in hairy cell leukemia is discussed.
在1984年5月至1985年12月期间，一家机构对61例毛细胞白血病患者使用（重组或天然）α-干扰素进行治疗。本文呈现了治疗7个月或12个月后所获得的反应，并对39例治疗停止超过12个月的患者进行了随访评估。治疗开始时的临床或组织学参数以及所使用干扰素的给药时间类型均无法预测反应质量。治疗结束时血细胞计数正常的患者，中性粒细胞减少至低于1.10(9)/l之前的中位时间间隔为12个月。然而，最初存在严重中性粒细胞减少或白细胞增多症的患者在治疗停止后早期复发更为常见。本文还讨论了毛细胞白血病的治疗策略。
